Tumor Bank Ovarian Cancer

Wir forschen für Sie

Herzlich Willkommen bei der AG TOC (Tumor Bank Eierstockkrebs / Ovarian Cancer).

Die AG TOC ist eine Gruppe engagierter Wissenschaftler, die sich auf Eierstockkrebs-Forschung und Seltene Gynäkologische Tumore spezialisiert haben.

Weitere Informationen finden Sie auch beim TOC Netzwerk.

Sie befinden sich hier:

Forschungsschwerpunkte

Das Tumor Bank Ovarian Cancer - Netzwerk (TOC) umfasst aktuell 13 rekrutierende Zentren und stellt mit Proben und klinischen Daten von über 6500 eingeschlossenen Ovarialkarzinompatientinnen weltweit die größte Tumorbank auf diesem Gebiet dar.

Dieses umfangreiche Probenkollektiv ermöglicht es uns, in Zusammenarbeit mit unseren nationalen und internationalen Kollaborationspartnern, zahlreiche translationale Forschungsprojekte durchzuführen.

Neben dem klinischen Management und der Durchführung von Studien beim Ovarialkarzinom hat unser Zentrum eine starke Erfolgsbilanz, die auf unserer TOC Biobank basiert und sich in über 200 Publikationen in renommierten Fachzeitschriften widerspiegelt.

Webseite: www.toc-network.de

Inhaltsübersicht

Laufende Projekte

Untersuchung der molekularbiologischen Grundlagen der Chemotherapie-Resistenzmechansimen im primären und rezidivierenden Ovarialkarzinom (Projektleiterin: Prof. Dr. Elena Ioana Braicu)
Etablierung von prognostischen Peptidsignaturen für Patientinnen im Frühstadium mit schlecht-differenziertem, serösen Ovarialkarzinom mittels MALDI-Imaging (Projektleiterin: Prof. Dr. Elena Ioana Braicu)
Identifikation und Evaluierung innovativer therapeutischer Strategien für spezifische molekulare Subtypen beim schlecht differenzierten serösen Ovarialkarzinom (Projektleiter: Dr. Hagen Kulbe)
Klassifikation der molekularen Subtypen des schlecht-differenzierten serösen Ovarialkarzinoms mittels bildgebender Massenspektrometrie (Projektleiterin: Prof. Dr. Elena Ioana Braicu)
Aufklärung von Resistenzmechanismen gegenüber PARP-Inhibitoren für die Entwicklung neuer therapeutischer Ansätze beim schlecht differenzierten serösen Ovarialkarzinom (Projektleiterin: Prof. Dr. Elena Ioana Braicu)
Verstehen der molekularbiologischen Grundlagen des low-grade serösen Ovarialkarzinoms – Kollaboration BIH_ PeDiOn (Projektleiterin: Prof. Dr. Elena Ioana Braicu)
Dostarlimab and Niraparib (PARPi) combination therapy in gynaecarcinosarcoma: Identification of response-predictive biomarkers and resistance mechanisms – ROCSANbio (Projektleiterin: Prof. Dr. Elena Ioana Braicu)
Molekulare Grundlagen des schlecht-differenzierten serösen Ovarialkarzinoms bei Patientinnen mit außergewöhnlichem Langzeitüberleben (Projektleiterin: Prof. Dr. Elena Ioana Braicu)
Prädiktive Signaturen für neo-adjuvante Chemotherapie beim Eierstockkrebs: Zusatzprogramm zur TRUST-Studie – DKTK Projekt (Projektleiter: Prof. Dr. Jalid Sehouli)
Multimodale klinische Massenspektrometrie für die Analyse der Therapieresistenz (Kollaboration: Charité Comprehensive Cancer Center)
T-Zell-Diversität als potenzieller blut-basierender Biomarker beim Ovarialkarzinom (Projektleiterin: Prof. Dr. Elena Ioana Braicu)
HELP-ER: Kann der Erfolg einer Rezidiv-OP vorab eingeschätzt werden? (Projektleiterin: Prof. Dr. Elena Ioana Braicu)
Entwicklung neuartiger systemischer Therapien beim humanen ovarialen Klarzellkarzinom (Projektleiter: Dr. Hagen Kulbe)

Publikationen

Braicu EI, Mustea A, Toliat MR, Pirvulescu C, Könsgen D, Sun P, Nurnberg P, Lichtenegger W, Sehouli J. Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients. Gynecol Oncol. 2007 Mar;104(3):680-5. Epub 2006 Dec 1. IF=3.92
Mustea A, Pirvulescu C, Könsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine. 2008 Apr;42(1):77-84. IF=3.148
Mustea A, Braicu EI, Könsgen D, Yuan S, Sun PM, Stamatian F, Lichtenegger W, Chen FC, Chekerov R, Sehouli J. Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. Cytokine. 2009 Jan;45(1):8-11. IF=3.148
Fotopoulou C, Savvatis K, Braicu EI, Brink-Spalink V, Darb-Esfahani S, Lichtenegger W, Sehouli J. Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome. Gynecol Oncol. 2010 Nov;119(2):285-90. IF: 3,92
Pils D, Wittinger M, Petz M, Gugerell A, Gregor W, Alfanz A, Horvat R, Braicu EI, Sehouli J, Zeillinger R, Mikulits W, Krainer M. BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment. Gynecol Oncol. 2010 May;117(2):189-97. IF: 3,92
Fotopoulou C, Richter R, Braicu EI, Kuhberg M, Feldheiser A, Schefold JC, Lichtenegger W, Sehouli J. Impact of Obesity on Operative Morbidity and Clinical Outcome in Primary Epithelial Ovarian Cancer after Optimal Primary Tumor Debulking. Ann Surg Oncol. 2011 Mar 11. IF: 4,12
Wynendaele J, Böhnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, Sbrzesny N, Kubitza D, Wolf A, Gradhand E, Balschun K, Braicu I, Sehouli J, Darb-Esfahani S, Denkert C, Thomssen C, Hauptmann S, Lund A, Marine JC, Bartel F. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res. 2010 Dec 1;70(23):9641-9. IF=9.13
Fotopoulou C, Richter R, Braicu IE, Schmidt SC, Neuhaus P, Lichtenegger W, Sehouli J. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol. 2011 Jan;18(1):49-57. IF: 4,12
Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011 Sep 27;105(7):890-6. doi: 10.1038/bjc.2011.328. IF=6.176
Braicu EI, Sehouli J, Richter R, Pietzner K, Lichtenegger W, Fotopoulou C. Primary versus secondary cytoreduction for epithelial ovarian cancer: A paired analysis of tumour pattern and surgical outcome. Eur J Cancer. 2011 Jul 12. IF=6.759
Braicu EI, Sehouli J, Richter R, Pietzner K, Denkert C, Fotopoulou C. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. Br J Cancer. 2011 Dec 6;105(12):1818-24. doi: 10.1038/bjc.2011.455. IF=6.176
Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N. Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. Br J Cancer. 2011 Nov 8;105(10):1593-9. doi: 10.1038/bjc.2011.433. IF=6.176
Sehouli J, Papanikolaou G, Braicu EI, Pietzner K, Neuhaus P, Fotopoulou C. Feasibility of surgery after systemic treatment with the humanized recombinant antibody bevacizumab in heavily pretreated patients with advanced epithelial ovarian cancer. Ann Surg Oncol. 2012 Apr;19(4):1326-33. doi: 10.1245/s10434-011-2134-0. IF=4.12
Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M, Altevogt P. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation. Ann Oncol. 2012 Jul;23(7):1795-802. doi: 10.1093/annonc/mdr568. IF=13.926
Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J. “Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.” Ann Surg Oncol. 2013 Apr;20(4):1348-54. IF: 4,12
Pils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, Tong D, Zeillinger R, Braicu EI, Sehouli J, Krainer M. “Methylation status of TUSC3 is a prognostic factor in ovarian cancer.” Cancer. 2013 Mar 1;119(5):946-54. IF: 5,068
Fotopoulou C, Savvatis K, Kosian P, Braicu IE, Papanikolaou G, Pietzner K, Schmidt SC, Sehouli J. “Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?” Br J Cancer. 2013 Jan 15;108(1):32-8. IF: 5,08
Biskup K, Braicu EI, Sehouli J, Fotopoulou C, Tauber R, Berger M, Blanchard V. “Serum glycome profiling: a biomarker for diagnosis of ovarian cancer.” J Proteome Res. 2013 Sep 6;12(9):4056-63. IF: 5,05
Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF. “Association of myeloperoxidase with ovarian cancer.” Tumour Biol. 2014 Jan;35(1):141-8. IF: 2,51
Türbachova I, Schwachula T, Vasconcelos I, Mustea A, Baldinger T, Jones KA, Bujard H, Olek A, Olek K, Gellhaus K, Braicu I, Könsgen D, Fryer C, Ravot E, Hellwag A, Westerfeld N, Gruss OJ, Meissner M, Hasan MT, Weber M, Hoffmüller U, Zimmermann S, Loddenkemper C, Mahner S, Babel N, Berns E, Adams R, Zeilinger R, Baron U, Vergote I, Maughan T, Marme F, Dickhaus T, Sehouli J, Olek S. “The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.” Epigenetics. 2013 Nov 1;8(11):1226-35. IF: 4,58
Braicu EI, Chekerov R, Richter R, Pop C, Nassir M, Loefgren H, Stamatian F, Muallem MZ, Hall C, Fotopoulou C, Sehouli J, Pietzner K. “HE4 Expression in Plasma Correlates with Surgical Outcome and Overall Survival in Patients with First Ovarian Cancer Relapse. Ann Surg Oncol.” 2013 Nov 12 . IF: 4,12
Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI. “BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).” - Eur J Cancer. 2014 May 30. IF: 5,06
Schwedler C, Kaup M, Petzold D, Hoppe B, Braicu EI, Sehouli J, Ehlers M, Berger M, Tauber R, Blanchard V. “Sialic acid methylation refines capillary electrophoresis laser-induced fluorescence analyses of immunoglobulin G N-glycans of ovarian cancer patients.” Electrophoresis. 2014 Apr;35(7):1025-31. IF: 3,26
Koensgen D, Bruennert D, Ungureanu S, Sofroni D, Braicu EI, Sehouli J, Sümnig A, Delogu S, Zygmunt M, Goyal P, Evert M, Olek S, Biebler KE, Mustea A. “Polymorphism of the IL-8 gene and the risk of ovarian cancer.” Cytokine. 2015 Feb;71(2):334-8. IF: 2,51
Schwedler C, Kaup M, Weiz S, Hoppe M, Braicu EI, Sehouli J, Hoppe B, Tauber R, Berger M, Blanchard V. “Identification of 34 N-glycan isomers in human serum by capillary electrophoresis coupled with laser-induced fluorescence allows improving glycan biomarker discovery.” Anal Bioanal Chem. 2014 Nov;406(28):7185-93. IF: 3,43
Despierre E, Moisse M, Yesilyurt B, Sehouli J, Braicu I, Mahner S, Castillo-Tong DC, Zeillinger R, Lambrechts S, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I. “Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.” Gynecol Oncol. 2014 Dec;135(3):415-22. IF: 3,92
Okamoto A, Sehouli J, Yanaihara N, Hirata Y, Braicu I, Kim BG, Takakura S, Saito M, Yanagida S, Takenaka M, Yamaguchi N, Morikawa A, Tanabe H, Yamada K, Yoshihara K, Enomoto T, Itamochi H, Kigawa J, Matsumura N, Konishi I, Aida S, Aoki Y, Ishii N, Ochiai K, Akiyama T, Urashima M. “Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.” PLoS One. 2015 Feb 6;10(2):e0116977. IF: 3,23
Gasimli K, Braicu EI, Richter R, Chekerov R, Sehouli J. “Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.” Ann Surg Oncol. 2015 Aug;22(8):2729-37. IF: 4,12
Seeber A, Braicu I, Untergasser G, Nassir M, Fong D, Botta L, Gastl G, Fiegl H, Zeimet A, Sehouli J, Spizzo G. “Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.” Oncotarget. 2015 Jul 10. IF: 6,35
Ganapathi MK, Jones WD, Sehouli J, Michener CM, Braicu IE, Norris EJ, Biscotti CV, Vaziri SA, Ganapathi RN. “Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer.” Int J Cancer. 2015 Aug 27. IF: 5,08
Arsenic R, Braicu EI, Letsch A, Dietel M, Sehouli J, Keilholz U, Ochsenreither S. “Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.” BMC Cancer. 2015 Oct 24;15:784. IF: 3,36
Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van Nieuwenhuysen E, Concin N, Marth C, Hall C, Mahner S, Woelber L, Sehouli J, Braicu EI. “The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.” Tumour Biol. 2015 Sep IF: 3,61
Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Jöhrens K. “Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.” Oncotarget. 2016 Jan 12;7(2):1486-99. IF: 6, 62
Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I. “Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.” Eur J Cancer. 2016 Jan;53:51-64. IF: 5,417 Taube ET, Denkert C, Sehouli J, Kunze CA, Dietel M, Braicu I, Letsch A, Darb-Esfahani S. “Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.” Gynecol Oncol. 2016 Mar;140(3):494-502 IF: 3,774
Gasimli K, Braicu EI, Nassir M, Richter R, Babayeva A, Chekerov R, Darb-Esfahani S, Sehouli J, Muallem MZ. “Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.” Ann Surg Oncol. 2016 Apr;23(4):1279-86. IF: 3,930
Dimitrova D, Ruscito I, Olek S, Richter R, Hellwag A, Türbachova I, Woopen H, Baron U, Braicu EI, Sehouli J. “Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.” Tumour Biol. 2016 Jun 14. IF: 2,84
Rohr I, Braicu EI, En-Nia A, Heinrich M, Richter R, Chekerov R, Dechend R, Heidecke H, Dragun D, Schäfer R, Gorny X, Lindquist JA, Brandt S, Sehouli J, Mertens PR. “Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).” Cytokine. 2016 Sep;85:157-64.IF: 2,874
Svoboda M, Meshcheryakova A, Heinze G, Jaritz M, Pils D, Castillo-Tong DC, Hager G, Thalhammer T, Jensen-Jarolim E, Birner P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Zimmermann P, Zeillinger R, Mechtcheriakova D. “AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.” BMC Genomics. 2016 Aug 16;17(1):643. doi: 10.1186/s12864-016-3001-y.IF: 3.867
Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, Dietel M, Aittokallio T, Markowetz F, Denkert C, Sehouli J, Frezza C, Darb-Esfahani S, Braicu EI. “Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.” Cancer Res. 2016 Feb 15;76(4):796-804. IF: 9,329
Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A, Cunnea P, Gabra H, Braicu EI, Sehouli J, Darb-Esfahani S, Vanderstichele A, Vergote I, Kreuzinger C, Cacsire Castillo-Tong D, Wisman GB, Berns EM, Siddiqui N, Paul J, Brown R. “Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients.” Clin Cancer Res. 2016 Sep 23.IF=8.738
Vanderstichele A, Busschaert P, Smeets D, Landolfo C, Van Nieuwenhuysen E, Leunen K, Neven P, Amant F, Mahner S, Braicu EI, Zeilinger R, Coosemans A, Timmerman D, Lambrechts D, Vergote I. Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. Clin Cancer Res. 2017 May 1;23(9):2223-2231. doi: 10.1158/1078-0432.CCR-16-1078. IF= 9.122
Biskup K, Braicu EI, Sehouli J, Tauber R, Blanchard V. The ascites N-glycome of epithelial ovarian cancer patients. J Proteomics. 2017 Mar 22;157:33-39. doi: 10.1016/j.jprot.2017.02.001.IF=IF=3.867
Phelps DL, Borley JV, Flower KJ, Dina R, Darb-Esfahani S, Braicu I, Sehouli J, Fotopoulou C, Wilhelm-Benartzi CS, Gabra H, Yazbek J, Chatterjee J, Ip J, Khan H, Likos-Corbett MT, Brown R, Ghaem-Maghami S. Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. Br J Cancer. 2017 May 9;116(10):1287-1293. doi: 10.1038/bjc.2017.83. IF=5.569
Pfarr N, Darb-Esfahani S, Leichsenring J, Taube E, Boxberg M, Braicu I, Jesinghaus M, Penzel R, Endris V, Noske A, Weichert W, Schirmacher P, Denkert C, Stenzinger A. Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. Genes Chromosomes Cancer. 2017 Oct;56(10):758-766. doi: 10.1002/gcc.22480. IF=3.686
Koensgen D, Stope MB, Tuerbachova I, Bruennert D, Kohlmann T, Braicu I, Sehouli J, Denkert C, Darb-Esfahani S, Stickeler E, Sofroni D, Dahl E, Mustea A. Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network. Gynecol Obstet Invest. 2017 Jul 22. doi: 10.1159/000479027. IF=1.415
Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Jöhrens K, Vergote I, Vanderstichele A, Boeckx B, Lambrechts D, Gabra H, Wisman GBA, Trillsch F, Heinze G, Horvat R, Polterauer S, Berns EMJJ, Theillet CG, Cacsire Castillo-Tong D. A complex network of tumor microenvironment in human high grade serous ovarian cancer. Clin Cancer Res. 2017 Oct 2. pii: clincanres.1159.2017. doi: 10.1158/1078-0432.CCR-17-1159. IF= 9.122
Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016.
IF: 5.06
Elena Ioana Braicu, Silvia Darb-Esfahani, Wolfgang D. Schmitt, Kaisa M. Koistinen, Laura Heiskanen, Päivi Pöhö, Jan Budczies, Marc Kuhberg, Manfred Dietel, Christian Frezza, Carsten Denkert, Jalid Sehouli, Mika Hilvo. High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. Oncotarget. doi.org/10.18632/oncotarget.22076. Published on 26.10.17. IF: 5.16
Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeilinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF. Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. PLoS One. 2017 Dec 15;12(12):e0189641. doi:10.1371/journal.pone.0189641.IF=3.54
Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. Gynecol Oncol. 2018 Apr;149(1):155-162. doi: 10.1016/j.ygyno.2018.01.022.IF=4.959
Severi L, Losi L, Fonda S, Taddia L, Gozzi G, Marverti G, Magni F, Chinello C, Stella M, Sheouli J, Braicu EI, Genovese F, Lauriola A, Marraccini C, Gualandi A, D'Arca D, Ferrari S, Costi MP. Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer. Front Pharmacol. 2018 May 8;9:454. doi: 10.3389/fphar.2018.00454.IF=3.83
Svoboda M, Mungenast F, Gleiss A, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Jäger W, Mechtcheriakova D, Cacsire-Tong D, Zeillinger R, Thalhammer T, Pils D. Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. Front Pharmacol. 2018 Aug 7;9:842. doi: 10.3389/fphar.2018.00842.IF=3.831
Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I*, Darb-Esfahani S*. Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia. 2018 Mar;20(3):280-288. doi:
10.1016/j.neo.2018.01.007.IF: 5.006
Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI. The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. Gynecol Oncol. 2018 Jul;150(1):151-157. doi: 10.1016/j.ygyno.2018.05.006. IF=4.540
Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study). Br J Cancer. 2018 Jun 29. doi: 10.1038/s41416-018-0157-z. IF=6.176
Darb-Esfahani S, Kolaschinski I, Trillsch F, Mahner S, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Wienert S, Taube ET, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI. Morphology and tumor-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival. Histopathology. 2018 Jul 14. doi: 10.1111/his.13711. IF=3.267
Niemi RJ*, Braicu EI*, Kulbe H, Koistinen KM, Sehouli J, Puistola U, Mäenpää JU, Hilvo M. Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism. Br J Cancer. 2018 Oct 8. doi: 10.1038/s41416-018-0270-z. IF=6.176
Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. Br J Cancer. 2018 Oct;119(9):1060-1066. doi: 10.1038/s41416-018-0268-6. IF=5.922
Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube E, Plett H. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the tumor bank ovarian cancer network. Hum Pathol. 2018 Nov 11. pii: S0046-8177(18)30417-9. doi: 10.1016/j.humpath.2018.10.020. IF=3.125
Klein O, Kanter F, Kulbe H, Jank P, Denkert C, Nebrich G, Schmitt WD, Wu Z, Kunze CA, Sehouli J, Darb-Esfahani S, Braicu I, Lellmann J, Thiele H, Taube ET. MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods. Proteomics Clin Appl. 2019 Jan;13(1):e1700181. doi: 10.1002/prca.201700181. IF=3.567
Kessler M, Hoffmann K, Fritsche K, Brinkmann V, Mollenkopf HJ, Thieck O, Teixeira da Costa AR, Braicu EI, Sehouli J, Mangler M, Berger H, Meyer TF. Chronic Chlamydia infection in human organoids increases stemness and promotes age-dependent CpG methylation. Nat Commun. 2019 Mar 18;10(1):1194. doi: 10.1038/s41467-019-09144-7. PubMed PMID: 30886143; PubMed Central PMCID: PMC6423033. IF=12.353
Meshcheryakova A, Svoboda M, Jaritz M, Mungenast F, Salzmann M, Pils D, Cacsire Castillo-Tong D, Hager G, Wolf A, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Birner P, Zimmermann P, Brindley DN, Heinze G, Zeillinger R, Mechtcheriakova D. Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer. Comput Struct Biotechnol J. 2019 Apr 10;17:537-560. doi: 10.1016/j.csbj.2019.04.004. PMID: 31049165; PMCID: PMC6479272. IF=5.11
Canaz E, Grabowski JP, Richter R, Braicu EI, Chekerov R, Sehouli J. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base. Gynecol Oncol. 2019 Sep;154(3):539-546. doi: 10.1016/j.ygyno.2019.06.014. Epub 2019 Jun 21. PMID: 31230821. IF=4.54
Wafa M, Braicu EI, Muallem MZ, Richter R, Taube E, Sehouli J, Grabowski JP. Incidence and Pattern of Spread of Lymph Node Metastasis in Patients With Low-grade Serous Ovarian Cancer. Anticancer Res. 2019 Oct;39(10):5617-5621. doi: 10.21873/anticanres.13757. PMID: 31570458.IF=1.937
Panoutsopoulou K, Avgeris M, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Vanderstichele A, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A. miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. Carcinogenesis. 2020 Jun 17;41(4):442-451. doi: 10.1093/carcin/bgz163. PMID: 31586203. IF=5.33
Grabowski JP, Martinez Vila C, Richter R, Taube E, Plett H, Braicu E, Sehouli J. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer. Int J Gynecol Cancer. 2020 Apr;30(4):498-503. doi: 10.1136/ijgc-2019-000976. Epub 2020 Jan 28. PMID: 31996397.IF=2.095
Hoffmann K, Berger H, Kulbe H, Thillainadarasan S, Mollenkopf HJ, Zemojtel T, Taube E, Darb-Esfahani S, Mangler M, Sehouli J, Chekerov R, Braicu EI, Meyer TF, Kessler M. Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment. EMBO J. 2020 Mar 16;39(6):e104013. doi: 10.15252/embj.2019104013. Epub 2020 Feb 3. PMID: 32009247; PMCID: PMC7073464. IF=9.96
Jones WD, Michener CM, Biscotti C, Braicu I, Sehouli J, Ganapathi MK, Ganapathi RN. RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers. Cancers (Basel). 2020 Mar 7;12(3):620. doi: 10.3390/cancers12030620. PMID: 32156016; PMCID: PMC7139955. IF=6.126
Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, Ruscito I, Braicu EI, Sehouli J, Ignatov A, Yu H, Katsaros D, Mills GB, Lu KH, Carey MS, Timms KM, Kupryjanczyk J, Rzepecka IK, Podgorska A, McAlpine JN, Swisher EM, Bernards SS, O'Riain C, O'Toole S, O'Leary JJ, Bowtell DD, Thomas DM, Prieske K, Joosse SA, Woelber L, Chaudhry P, Häfner N, Runnebaum IB, Hennessy BT. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2020 May 15:djaa070. doi: 10.1093/jnci/djaa070. Epub ahead of print. PMID: 32413141. IF=12.58
Wieczorek M, Braicu EI, Oliveira-Ferrer L, Sehouli J, Blanchard V. Immunoglobulin G Subclass-Specific Glycosylation Changes in Primary Epithelial Ovarian Cancer. Front Immunol. 2020 May 15;11:654. doi: 10.3389/fimmu.2020.00654. PMID: 32477323; PMCID: PMC7242562. IF=5.085
Naskou J, Beiter Y, van Rensburg R, Honisch E, Rudelius M, Schlensog M, Gottstein J, Walter L, Braicu EI, Sehouli J, Darb-Esfahani S, Staebler A, Hartkopf AD, Brucker S, Wallwiener D, Beyer I, Niederacher D, Fehm T, Templin MF, Neubauer H. EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. Mol Cancer Res. 2020 Feb;18(2):278-286. doi: 10.1158/1541-7786.MCR-19-0141. Epub 2019 Nov 8. PMID: 31704732. IF=4.63
Guan J, Darb-Esfahani S, Richter R, Taube ET, Ruscito I, Mahner S, Woelber L, Prieske K, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium. J Cancer Res Clin Oncol. 2019 Apr;145(4):1063-1073. doi: 10.1007/s00432-019-02877-4. IF=3.081
Kulbe H, Otto R, Darb-Esfahani S, Lammert H, Abobaker S, Welsch G, Chekerov R, Schäfer R, Dragun D, Hummel M, Leser U, Sehouli J, Braicu EI. Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer. Cells. 2019 Jul 12;8(7):713. doi: 10.3390/cells8070713. PMID: 31336942; PMCID: PMC6678810. IF=4.829
Kulbe H, Klein O, Wu Z, Taube ET, Kassuhn W, Horst D, Darb-Esfahani S, Jank P, Abobaker S, Ringel F, du Bois A, Heitz F, Sehouli J, Braicu EI. Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging. Cancers (Basel). 2020 Jul 22;12(8):2000. doi: 10.3390/cancers12082000. PMID: 32707805; PMCID: PMC7463791. IF=6.126
Baum J, Braicu EI, Hunsicker O, Vergote I, Concin N, Van Nieuwenhuysen E, Feldheiser A, Achimas-Cadariu P, Darb-Esfahani S, Berger A, Fetica B, Mahner S, Papadia A, Wölber L, Gasparri ML, Vanderstichele A, Benedetti Panici P, Mueller MD, Ruscito I, Woopen H, Sehouli J. Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis. Int J Gynecol Cancer. 2021 Feb 9:ijgc-2020-002023. doi: 10.1136/ijgc-2020-002023. IF=2.192 IF=2.095
Könsgen D, Klinkmann G, Kaul A, Diesing K, Sehouli J, Braicu I, Sümnig A, Erb HHH, Stope MB, Mustea A. Soluble heat-shock protein 27 in blood serum is a non-invasive prognostic biomarker for ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2020 Dec;255:154-159. doi: 0.1016/j.ejogrb.2020.10.044. IF=1.868
Grabowski JP, Glajzer J, Richter R, Plett H, Muallem MZ, Braicu EI, Taube E, Sehouli J. Lymphovascular space invasion and Ki67 as predictors of lymph node metastasis in primary low grade serous ovarian cancer. Int J Gynecol Cancer. 2021 Jan;31(1):98-103. doi: 10.1136/ijgc-2020-001950. IF=2.192

Struktur des TOC-Netzwerkes

Stanford an der Charité: Frauenheilkunde in Lehre und Forschung

Das Berliner Zentrum des Bing Overseas Studies Program (BOSP) der Stanford Universität und der Fächerverbund Frauenheilkunde der Charité – Universitätsmedizin Berlin kooperieren ab 2022 auf dem Gebiet der Lehre und Forschung. Die Arbeitsgruppe Tumor Bank Eierstockkrebs (AG TOC) des Gynäkologisches Tumorzentrums bietet zunächst Forschungspraktika für Bachelorstudierende an, die zuvor bei "Stanford in Berlin" Kurse belegen und ein Stipendium des "Krupp Internship Program for Stanford Students in Germany" erhalten. Diese Praktika eignen sich besonders für Studierende der Biologie und Humanbiologie, der Chemie und Bioinformatik. Im Weiteren ist angestrebt, ein Lehrmodul Frauenheilkunde im Frühjahrstrimester des Berliner BOSP-Zentrums anzubieten, das speziell für angehende Studierende der Medizin und ihre Praktika in der AG TOC gedacht ist, aber auch qualifizierten Studierenden offensteht, die anschließend kein Praktikum absolvieren.

Ansprechpartnerinnen:

Prof. Dr.med. Elena Ioana Braicu, Frauenklink der Charité – Universitätsmedizin Berlin

Dr. Karen Kramer, Direktorin, BOSP/Berlin, Stanford University